AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data
In competition with Boehringer And Lilly’s Jardiance
Executive Summary
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.
You may also be interested in...
AstraZeneca’s Farxiga Flies Across $1bn Barrier
First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.
Boehringer Pharma Chief Confident Of Continued Success For Jardiance
Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.
BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.